UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~Pursuant~~ Date toof ~~Section~~Report 13(Date ORof ~~15(d~~earliest event reported) ofFebruary 12, 2009

The Securities Exchange Act of 1934

Synovics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


Nevada	0-22011	86-0760991
(State or other jurisdiction of	(Commission File Number)	(IRS Employer Identification No.)
incorporation)


5360 Northwest 35th Avenue, Ft. Lauderdale, FL		33309
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (954) 486-4590


(Former name or former address, if changed since last report.)

Date of Report (Date of earliest event reported) August 22, 2008

Synovics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Nevada	0-22011	86-0760991
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5360 Northwest 35th Avenue, Ft. Lauderdale, FL	33309
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (954) 486-4590

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Soliciting~~ Item ~~material~~4.01 Changes ~~pursuant~~in toRegistrant’s ~~Rule~~Certifying ~~14a-12~~Accountant ~~under the Exchange Act (17 CFR 240.14a-12)~~

~~o Pre-commencement~~ On ~~communications~~February ~~pursuant~~12, to2009, ~~Rule~~Miller, ~~14d-2~~Ellin & Company, LLP (b“Miller Ellin”), ~~under~~the Registrant’s independent accountant and the ~~Exchange~~principal ~~Act~~accountant engaged to audit its financial statements, notified the Registrant that it consummated a merger (17the ~~CFR~~“Merger”) ~~240.14d-2~~of its practice into the practice of Rosen Seymour Shapss Martin & Company LLP (b“Rosen Seymour”)), with Rosen Seymour the resulting surviving legal entity, such Merger effective as of January 1, 2009. As of the date of the Merger, Rosen Seymour, as a matter of law, succeeded Miller Ellin as the Registrant’s independent accountants, and the Registrant formally engaged Rosen Seymour, as successor in interest of Miller Ellin, as its new independent accountant and principal accountant to audit its financial statements. The foregoing change in auditor was approved by the Registrant’s board of directors.

~~o Pre-commencement~~ The audit ~~communications~~report ~~pursuant~~of Miller Ellin on the Registrant’s financial statements for the fiscal years ended October 31, 2007 and October 31, 2008 expressed an unqualified opinion and included an explanatory paragraph relating to ~~Rule~~the ~~13e-4(c)~~Registrant’s ability ~~under~~to continue as a going concern. Such audit reports did not contain any other adverse opinion or disclaimer of opinion or qualification. During Registrant’s two most recent fiscal years and the ~~Exchange~~period ~~Act~~from ~~(17~~the ~~CFR~~end ~~240~~of the most recently completed fiscal year through the date of the Merger, there were no disagreements with Miller Ellin on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which, if not resolved to the satisfaction of Miller Ellin, would have caused such entity to make reference to such disagreements in its reports.~~13e~~ During the Registrant’s two most recent fiscal years and through the date of the Merger, no “reportable events” (as described in Item 304(a)(1)(v) of Regulation S-4K) occurred that would be required by Item 304(ca)(1)(v) to be disclosed in this report.

Item 1.01	Entry into a Material Definitive Agreement
Item 3.02	Unregistered Sales of Equity Securities

During Registrant’s two most recent fiscal years and the period from the end of the most recently completed fiscal year through the date of the Merger, neither the Registrant nor anyone on its behalf consulted Rosen Seymour regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrant’s financial statements, and either a written report was provided to the Registrant or oral advice was provided that Rosen Seymour concludes was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement” ”(as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to such item) or “reportable events” (as described in Item 304(a)(1)(v) of Regulation S-K).

As The ~~previously~~Registrant ~~reported~~has inrequested ~~Current~~Miller ~~Report~~Ellin onand ~~Form~~Rosen ~~8-K~~Seymour ~~dated~~to ~~May~~review ~~15, 2008,~~ the ~~Registrant~~disclosures ~~completed~~contained anin ~~initial~~this ~~closing~~report ofand ahave ~~Series~~asked Ceach ~~Preferred~~of ~~Stock~~them ~~offering~~to (furnish the ~~“Series~~Registrant Cwith ~~Offering”). On~~a ~~August~~currently ~~22,~~dated letter ~~2008,~~addressed to the ~~Registrant~~SEC ~~completed~~containing anany ~~additional~~new ~~closing~~information, clarification of ~~its~~the ~~Series~~expression Cof ~~Offering~~the ~~whereby~~Registrant’s inviews ~~consideration~~or ~~for~~the $1respects ~~million,~~in which it ~~sold~~does tonot ~~Svizera~~agree ~~Holdings~~with BVthe ~~(“Svizera”)~~statements ~~2,000~~made ~~shares~~by ofit ~~Series~~in Cresponse ~~Convertible~~to ~~Redeemable~~Item ~~Preferred Stock~~ 304(~~“Series~~a) Cof ~~Preferred~~Regulation ~~Stock”),~~S-K. ~~together~~A ~~with~~copy of ~~detachable~~each ~~warrants~~such ~~(the~~letter ~~“Warrants”)~~is tofiled ~~acquire~~as an ~~aggregate~~exhibit ofto ~~1,000,000~~this ~~shares of its common stock~~report.

~~The~~ ~~Series~~Item C Preferred stock is convertible into shares of the Registrant’s common stock at an initial rate of 1,000 shares of common stock for each share of Series C Preferred Stock subject to adjustment pursuant to the Certificate of Designations, Preferences and Rights of Series C Convertible Redeemable Preferred Stock and votes on an as-converted basis together with the Registrant’s common stock and any class of preferred stock entitled to vote with the Registrant’s common stock at any annual or special meeting of the Registrant9. ~~The Warrants are exercisable for a period of five years from the date of grant at an initial exercise price of $0~~01.75 Financial ~~per~~Statements ~~share, subject to adjustment for, among other things, stock splits, stock dividends, distributions, reclassifications~~ and ~~sales~~ ~~below~~Exhibits the exercise price. The shares of common stock issuable upon exercise of the Warrants will be registrable under the Registration Rights Agreement between the purchasers of Series C Preferred Stock and the Registrant. The proceeds from this additional closing are being used to retire indebtedness.

~~Svizera is~~ (a) ~~wholly-owned~~Not ~~subsidiary~~applicable. ~~of Maneesh Pharmaceuticals Ltd~~ (~~“Maneesh”~~b). ~~Maneesh~~Not ~~is controlled by Vinay Sapte and his brother Maneesh Sapte, and together with Jyotindra Gange are each designees of Maneesh on the Registrant’s five-member board~~applicable. ~~Svizera~~ ~~is the lead investor in the Series C Offering which, together with the above-referenced $1 million, invested an aggregate of $7 million in the Series C Offering~~ (~~including the “roll-over” of a 2008 Bridge Note in the principal amount of $1 million~~c). AsNot ~~a result of this closing, Maneesh beneficially owns 27,904,700 shares of the Registrant’s common stock~~applicable. (d) Exhibits

The securities were offered and sold to investors in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended.

	16.1	Letter dated March 17, 2009, from Miller Ellin & Company, LLP to the Securities and Exchange Commission

	16.2	Letter dated March 17, 2009, from Rosen Seymour Shapss Martin & Company LLP to the Securities and Exchange Commission

THIS CURRENT REPORT IS NOT AN OFFER OF SECURITIES FOR SALE. ANY SECURITIES SOLD IN CONNECTION WITH THE SERIES C OFFERING WILL NOT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION.

Item 9.01. Financial Statements and Exhibits (a) Not applicable.

(b)	Not applicable.
(c)	Not applicable.
(d)	Exhibits
	10.1	Form of Subscription Agreement*
	10.2	Form of Registration Rights Agreement*
	10.3	Form of Warrant*

* To be filed by amendment to Current Report on Form 8-K on May 15, 2008 and incorporated by reference herein.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~August 28~~ March 17, ~~2008~~2009

SYNOVICS PHARMACEUTICALS, INC. By: /s/ ~~Jyotindra~~Mahendra ~~Gange~~Desai Name: ~~Jyotindra~~Mahendra ~~Gange~~Desai Title: ~~Principal~~Chief ~~Executive~~Financial Officer

Filing Compare · Synovics Pharmaceuticals